Infantile Spasms – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Infantile spasms (IS), or West syndrome, one of the most recognized types of epileptic encephalopathy, constitutes a distinct and often catastrophic form of epilepsy of early infancy. The disorder presents with a unique seizure type, infantile spasms, characterized by flexor, extensor, and mixed flexor–extensor spasms; distinct electroencephalography (EEG) pattern of hypsarrhythmia; and psychomotor delay/arrest. IS can be classified by two etiologies: symptomatic and cryptogenic. Patients with symptomatic IS have a clearly defined underlying cause and/or significant developmental delay prior to the onset of spasms. In cryptogenic IS, no underlying cause is identified and normal development is present prior to the onset of spasms. Causes of IS may be prenatal, perinatal, or postnatal. Approximately 50% of cases have a prenatal cause, which includes central nervous system malformations, intrauterine insults, neurocutaneous syndromes such as tuberous sclerosis complex (TSC), metabolic disorders, and genetic syndromes such as Down’s syndrome.

The incidence of IS ranges from 3.7 to 4.2 per 10,000 live births. Most cases present at the peak age of onset between 3 and 7 months, with 90% of patients presenting in the first year; onset after 18 months is rare, although onset up to 4 years of age.

The competitive landscape of Infantile Spasms includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Infantile Spasms across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Infantile Spasms Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Infantile Spasms – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Tricaprilin          Cerecin Phase 1

2          GWP42003-P    GW Research Ltd          Phase 3

3          Ganaxolone      Marinus Pharmaceuticals           Phase 2

4          JBPOS0101      Bio-Pharm Solutions Co., Ltd.    Phase 2

5          TAK-935           Ovid Therapeutics Inc.   Phase 2

6          TAK-935           Takeda Phase 2